BioSpace News Archive

Median Technologies to Participate in the 2024 ASCO Annual Meeting, May 31 - June 4, 2024, McCormick Place, Chicago, IL, USA

Median Technologies announced that the Company will be participating in the 2024 American Society of Clinical Oncology Annual Meeting taking place from May 31 to June 4, McCormick Place, Chicago, IL, USA.

May 29, 2024
·
2 min read
Policy

Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study

Intelligent Bio Solutions Inc. announced the successful recruitment and commencement of screening for subjects in its pharmacokinetic study, a critical component of the Company’s FDA 510 regulatory pathway for clearance.

May 29, 2024
·
4 min read
Business

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

NurExone Biologic Inc., a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024, the highlights of which are included in this news release.

May 29, 2024
·
10 min read
Pharm Country

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution.

May 29, 2024
·
2 min read
BioCapital

Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of LaunchGeorgiamune receives U.S. FDA clearance for GIM-531 and begins phase II of clinical trial testing for GIM-122

Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announced the clearance of its second Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-531, a first-in-class oral treatment that selectively targets T-regulatory cells and spares other immune cells such as CD4 and CD8.

May 29, 2024
·
3 min read
Biotech Beach

Rakuten Medical to Host R&D Day Highlighting Recent Interim Data from Phase 1b/2 Clinical Trial of ASP-1929 Photoimmunotherapy in Combination with anti-PD-1 in r/m HNSCC

Rakuten Medical, Inc. today announced that it will host a virtual R&D Day on Thursday, June 20, 2024 at 1:00 pm ET / 10:00 am PT.

May 29, 2024
·
5 min read
BioMidwest

LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies at the 92nd European Atherosclerosis Society Congress

LIB Therapeutics Announces Positive Lerodalcibep Results from Two Phase 3 LIBerate Studies at the 92nd European Atherosclerosis Society Congress.

May 29, 2024
·
6 min read
Biotech Beach

Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

Illumina Inc. today announced some of its latest research being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31–June 4 in Chicago.

May 29, 2024
·
5 min read
Biotech Bay

CG Pharmaceuticals Prepares to Showcase Its Ongoing Phase 2 Study for Ivaltinostat in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

CG Pharmaceuticals, a company dedicated to advancing innovative therapies to improve the lives of patients with cancer, prepares to showcase its advancements in metastatic PDAC therapy.

May 29, 2024
·
2 min read
Biotech Bay

Octave® Bioscience, Inc. Announces Publication in Nature Communications

Octave ® Bioscience, Inc. today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.

May 29, 2024
·
5 min read